Trial ID: | L0907 |
Source ID: | IRCT2013122811763N15
|
Associated Drug: |
Symbiotic
|
Title: |
Effects of Symbiotic on inflammatory markers, liver function, lipid profile, sonographic findings and body composition in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
|
Acronym: |
--
|
Status: |
Not Recruiting
|
Study Results: |
No Results Available
|
Results: |
--
|
Conditions: |
NAFLD. <br>Fatty (change of) liver;Fatty (change of) liver
|
Interventions: |
Intervention 1: Daily oral consumption of Symbiotic supplement produced by Zist takhmir company with Familact commercial name contain 500 mg of seven Probiotic bacteria species and Fructooligosaccharides with below composition for two months: Lactobacillu
|
Outcome Measures: |
Fatty liver grade. Timepoint: before and after the intervention. Method of measurement: Ultrasonography.;Alt_Ast. Timepoint: before and after the intervention. Method of measurement: by laboratory analysis (blood tests).;Lipid profiles. Timepoint: before and after the intervention. Method of measurement: by laboratory analysis (enzymatic).;Inflammatory markers. Timepoint: before and after the intervention. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA).;Body composition. Timepoint: before and after the intervention. Method of measurement: Bioelectrical Impedance Assessment.nan
|
Sponsor/Collaborators: |
Vice chancellor for research, Isfahan University of Medical Sciences
|
Gender: |
All
|
Age: |
18 years60 years
|
Phases: |
Not applicable
|
Enrollment: |
80
|
Study Type: |
interventional
|
Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: This study will be a double blind clinical trial. The researcher and the patients will not know that each patient will be
|
Start Date: |
02/01/2014
|
Completion Date: |
--
|
Results First Posted: |
--
|
Last Update Posted: |
22 February 2018
|
Locations: |
Iran (Islamic Republic of)
|
URL: |
http://en.irct.ir/trial/11925
|